Evidence map›Paper›PMID 38062732›Full record

Trial reportThyroid : official journal of the American Thyroid Association2024

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre and 6 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thyroid : official journal of the American Thyroid Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 8 countries.

Jaume CapdevilaGastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.
Jolanta KrajewskaDepartment of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Jorge HernandoVall d'Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Bruce RobinsonDepartment of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Steven I ShermanDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Barbara JarzabDepartment of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Chia-Chi LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Fernanda VaismanDepartment of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Ana O HoffDepartment of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
Erika HitreDepartment of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary.
Daniel W BowlesDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Denise WilliamsonDepartment of Biostatistics, Exelixis, Inc., Alameda, California, USA.
Roman LevytskyyDepartment of Medical Affairs, Exelixis, Inc., Alameda, California, USA.
Jennifer OliverDepartment of Clinical Development, Exelixis, Inc., Alameda, California, USA.
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Marcia S BroseDepartment of Medical Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Exelixis (United States) · USHebron University · PSThe Maria Sklodowska-Curie National Research Institute of Oncology · PLInstituto Nacional de Câncer - INCA · BRNational Institute of Criminology · HUNational Taiwan University Hospital · TWSeoul National University Hospital · KRThe University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USUniversidade de São Paulo · BRUniversity of Colorado Anschutz Medical Campus · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenocarcinomaAnilidesAntineoplastic AgentsPyridinesQuinolinesThyroid NeoplasmsAgedHumansIodine RadioisotopesPhenylurea CompoundsProgression-Free SurvivalProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorSorafenibVascular Endothelial Growth Factor AAnilidesAntineoplastic AgentscabozantinibIodine RadioisotopeslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsPyridinesQuinolinesReceptors, Vascular Endothelial Growth FactorSorafenibVascular Endothelial Growth Factor AcabozantinibCOSMIC-311follicularlenvatinibpapillaryradioiodine-refractory differentiated thyroid cancer

Identifiers

PMID38062732
PMCPMC10951569
OpenAlexW4389486212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.